APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Influenza Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Influenza Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174002660320 December 2025193 pages

Choose your research edition.

Industry ResearchInfluenza Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Influenza Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Influenza Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenza Drugs include Novartis, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Serum Institute of India and Seqirus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Influenza Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Influenza Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Influenza Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Influenza Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Influenza Drugs Segment by Company

Novartis

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Serum Institute of India

Seqirus

Sanofi Pasteur

Protein Sciences Corporation

Emergent Biosolutions

Celgene

Bristol-Myers Squibb]

BioCryst Pharmaceuticals

Alvogen

Influenza Drugs Segment by Type

Oseltamivir Phosphate

Peramivir

Zanamivir

Other Influenza Drugs

Influenza Drugs Segment by Application

Adults

Chidren

Influenza Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Influenza Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenza Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Influenza Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Influenza Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Influenza Drugs Industry Trends Table 2. Influenza Drugs Industry Drivers Table 3. Influenza Drugs Industry Opportunities and Challenges Table 4. Influenza Drugs Industry Restraints Table 5. Global Influenza Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Influenza Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Influenza Drugs Sales by Manufacturers (K Tons) & (2021-2026) Table 8. Global Influenza Drugs Sales Market Share by Manufacturers Table 9. Global Influenza Drugs Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Influenza Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Influenza Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Influenza Drugs Manufacturers, Product Type & Application Table 13. Global Influenza Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Influenza Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oseltamivir Phosphate Table 17. Major Manufacturers of Peramivir Table 18. Major Manufacturers of Zanamivir Table 19. Major Manufacturers of Other Influenza Drugs Table 20. Global Influenza Drugs Sales by Type 2021 VS 2025 VS 2032 (K Tons) Table 21. Global Influenza Drugs Sales by Type (2021-2026) & (K Tons) Table 22. Global Influenza Drugs Sales by Type (2027-2032) & (K Tons) Table 23. Global Influenza Drugs Sales Market Share by Type (2021-2026) Table 24. Global Influenza Drugs Sales Market Share by Type (2027-2032) Table 25. Global Influenza Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Tons) Table 26. Global Influenza Drugs Revenue by Type (2021-2026) & (K Tons) Table 27. Global Influenza Drugs Revenue by Type (2027-2032) & (K Tons) Table 28. Global Influenza Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Influenza Drugs Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Adults Table 31. Major Manufacturers of Chidren Table 32. Global Influenza Drugs Sales by Application 2021 VS 2025 VS 2032 (K Tons) Table 33. Global Influenza Drugs Sales by Application (2021-2026) & (K Tons) Table 34. Global Influenza Drugs Sales by Application (2027-2032) & (K Tons) Table 35. Global Influenza Drugs Sales Market Share by Application (2021-2026) Table 36. Global Influenza Drugs Sales Market Share by Application (2027-2032) Table 37. Global Influenza Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Tons) Table 38. Global Influenza Drugs Revenue by Application (2021-2026) & (K Tons) Table 39. Global Influenza Drugs Revenue by Application (2027-2032) & (K Tons) Table 40. Global Influenza Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Influenza Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Influenza Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 43. Global Influenza Drugs Sales by Region (2021-2026) & (K Tons) Table 44. Global Influenza Drugs Sales Market Share by Region (2021-2026) Table 45. Global Influenza Drugs Sales Forecasted by Region (2027-2032) & (K Tons) Table 46. Global Influenza Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 48. North America Influenza Drugs Sales by Country (2021-2026) & (K Tons) Table 49. North America Influenza Drugs Sales by Country (2027-2032) & (K Tons) Table 50. Europe Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 51. Europe Influenza Drugs Sales by Country (2021-2026) & (K Tons) Table 52. Europe Influenza Drugs Sales by Country (2027-2032) & (K Tons) Table 53. Asia Pacific Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 54. Asia Pacific Influenza Drugs Sales by Country (2021-2026) & (K Tons) Table 55. Asia Pacific Influenza Drugs Sales by Country (2027-2032) & (K Tons) Table 56. South America, Middle East and Africa Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Tons) Table 57. South America, Middle East and Africa Influenza Drugs Sales by Country (2021-2026) & (K Tons) Table 58. South America, Middle East and Africa Influenza Drugs Sales by Country (2027-2032) & (K Tons) Table 59. Global Influenza Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Influenza Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Influenza Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Influenza Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Influenza Drugs Revenue Market Share by Region (2027-2032) Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis Influenza Drugs Product Portfolio Table 68. Novartis Recent Development Table 69. Roche Company Information Table 70. Roche Business Overview Table 71. Roche Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Roche Influenza Drugs Product Portfolio Table 73. Roche Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Eli Lilly Influenza Drugs Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Influenza Drugs Product Portfolio Table 83. Pfizer Recent Development Table 84. GlaxoSmithKline Company Information Table 85. GlaxoSmithKline Business Overview Table 86. GlaxoSmithKline Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline Influenza Drugs Product Portfolio Table 88. GlaxoSmithKline Recent Development Table 89. Bayer Company Information Table 90. Bayer Business Overview Table 91. Bayer Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Bayer Influenza Drugs Product Portfolio Table 93. Bayer Recent Development Table 94. AstraZeneca Company Information Table 95. AstraZeneca Business Overview Table 96. AstraZeneca Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. AstraZeneca Influenza Drugs Product Portfolio Table 98. AstraZeneca Recent Development Table 99. Serum Institute of India Company Information Table 100. Serum Institute of India Business Overview Table 101. Serum Institute of India Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Serum Institute of India Influenza Drugs Product Portfolio Table 103. Serum Institute of India Recent Development Table 104. Seqirus Company Information Table 105. Seqirus Business Overview Table 106. Seqirus Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Seqirus Influenza Drugs Product Portfolio Table 108. Seqirus Recent Development Table 109. Sanofi Pasteur Company Information Table 110. Sanofi Pasteur Business Overview Table 111. Sanofi Pasteur Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Sanofi Pasteur Influenza Drugs Product Portfolio Table 113. Sanofi Pasteur Recent Development Table 114. Protein Sciences Corporation Company Information Table 115. Protein Sciences Corporation Business Overview Table 116. Protein Sciences Corporation Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Protein Sciences Corporation Influenza Drugs Product Portfolio Table 118. Protein Sciences Corporation Recent Development Table 119. Emergent Biosolutions Company Information Table 120. Emergent Biosolutions Business Overview Table 121. Emergent Biosolutions Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Emergent Biosolutions Influenza Drugs Product Portfolio Table 123. Emergent Biosolutions Recent Development Table 124. Celgene Company Information Table 125. Celgene Business Overview Table 126. Celgene Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Celgene Influenza Drugs Product Portfolio Table 128. Celgene Recent Development Table 129. Bristol-Myers Squibb] Company Information Table 130. Bristol-Myers Squibb] Business Overview Table 131. Bristol-Myers Squibb] Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Bristol-Myers Squibb] Influenza Drugs Product Portfolio Table 133. Bristol-Myers Squibb] Recent Development Table 134. BioCryst Pharmaceuticals Company Information Table 135. BioCryst Pharmaceuticals Business Overview Table 136. BioCryst Pharmaceuticals Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. BioCryst Pharmaceuticals Influenza Drugs Product Portfolio Table 138. BioCryst Pharmaceuticals Recent Development Table 139. Alvogen Company Information Table 140. Alvogen Business Overview Table 141. Alvogen Influenza Drugs Sales (K Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Alvogen Influenza Drugs Product Portfolio Table 143. Alvogen Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Influenza Drugs Distributors List Table 147. Influenza Drugs Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Influenza Drugs Product Image Figure 2. Global Influenza Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza Drugs Sales (2021-2032) & (K Tons) Figure 5. Global Influenza Drugs Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Influenza Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oseltamivir Phosphate Image Figure 9. Peramivir Image Figure 10. Zanamivir Image Figure 11. Other Influenza Drugs Image Figure 12. Global Influenza Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 13. Global Influenza Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Influenza Drugs Sales Market Share by Type (2021-2032) Figure 15. Global Influenza Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 16. Global Influenza Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Influenza Drugs Revenue Market Share by Type (2021-2032) Figure 18. Adults Image Figure 19. Chidren Image Figure 20. Global Influenza Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 21. Global Influenza Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Influenza Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Influenza Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 24. Global Influenza Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Influenza Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 27. North America Influenza Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 29. Canada Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 30. Mexico Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 31. Europe Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 32. Europe Influenza Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 34. France Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 35. U.K. Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 36. Italy Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 37. Netherlands Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 38. Asia Pacific Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 39. Asia Pacific Influenza Drugs Sales Market Share by Country (2021-2032) Figure 40. China Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 41. Japan Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 42. South Korea Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 43. Southeast Asia Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 44. India Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 45. Australia Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 46. South America, Middle East and Africa Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 47. South America, Middle East and Africa Influenza Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 49. South Africa Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 50. Saudi Arabia Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 51. Turkey Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 52. Argentina Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 53. UAE Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 54. Egypt Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 55. Chile Influenza Drugs Sales and Growth Rate (2021-2032) & (K Tons) Figure 56. Global Influenza Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Influenza Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Influenza Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Influenza Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Influenza Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Influenza Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Influenza Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Influenza Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir Phosphate
  • Peramivir
  • Zanamivir
  • Other Influenza Drugs
Applications
  • Adults
  • Chidren
Companies covered
  • Novartis
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Serum Institute of India
  • Seqirus
  • Sanofi Pasteur
  • Protein Sciences Corporation
  • Emergent Biosolutions
  • Celgene
  • Bristol-Myers Squibb]
  • BioCryst Pharmaceuticals
  • Alvogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Influenza Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Influenza Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Influenza Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Influenza Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Influenza Drugs Market Dynamics
  1. 2.1 Influenza Drugs Industry Trends
  2. 2.2 Influenza Drugs Industry Drivers
  3. 2.3 Influenza Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza Drugs Industry Restraints
3 Influenza Drugs Market by Manufacturers
  1. 3.1 Global Influenza Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Influenza Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Influenza Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Influenza Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenza Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Influenza Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Influenza Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenza Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenza Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenza Drugs Tier 1, Tier 2, and Tier 3
4 Influenza Drugs Market by Type
  1. 4.1 Influenza Drugs Type Introduction
  2. 4.1.1 Oseltamivir Phosphate
  3. 4.1.2 Peramivir
  4. 4.1.3 Zanamivir
  5. 4.1.4 Other Influenza Drugs
  6. 4.2 Global Influenza Drugs Sales by Type
  7. 4.2.1 Global Influenza Drugs Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Influenza Drugs Sales by Type (2021-2032)
  9. 4.2.3 Global Influenza Drugs Sales Market Share by Type (2021-2032)
  10. 4.3 Global Influenza Drugs Revenue by Type
  11. 4.3.1 Global Influenza Drugs Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Influenza Drugs Revenue by Type (2021-2032)
  13. 4.3.3 Global Influenza Drugs Revenue Market Share by Type (2021-2032)
5 Influenza Drugs Market by Application
  1. 5.1 Influenza Drugs Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Chidren
  4. 5.2 Global Influenza Drugs Sales by Application
  5. 5.2.1 Global Influenza Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Influenza Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Influenza Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Influenza Drugs Revenue by Application
  9. 5.3.1 Global Influenza Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Influenza Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Influenza Drugs Revenue Market Share by Application (2021-2032)
6 Global Influenza Drugs Sales by Region
  1. 6.1 Global Influenza Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Influenza Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Influenza Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Influenza Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Influenza Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Influenza Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Influenza Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Influenza Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Influenza Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Influenza Drugs Revenue by Region
  1. 7.1 Global Influenza Drugs Revenue by Region
  2. 7.1.1 Global Influenza Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Influenza Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Influenza Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Influenza Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Influenza Drugs Revenue (2021-2032)
  8. 7.2.2 North America Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Influenza Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Influenza Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Influenza Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Influenza Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Influenza Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Influenza Drugs Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Influenza Drugs Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Influenza Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Influenza Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Influenza Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Influenza Drugs Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Serum Institute of India
  44. 8.8.1 Serum Institute of India Company Information
  45. 8.8.2 Serum Institute of India Business Overview
  46. 8.8.3 Serum Institute of India Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Influenza Drugs Product Portfolio
  48. 8.8.5 Serum Institute of India Recent Developments
  49. 8.9 Seqirus
  50. 8.9.1 Seqirus Company Information
  51. 8.9.2 Seqirus Business Overview
  52. 8.9.3 Seqirus Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Seqirus Influenza Drugs Product Portfolio
  54. 8.9.5 Seqirus Recent Developments
  55. 8.10 Sanofi Pasteur
  56. 8.10.1 Sanofi Pasteur Company Information
  57. 8.10.2 Sanofi Pasteur Business Overview
  58. 8.10.3 Sanofi Pasteur Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Pasteur Influenza Drugs Product Portfolio
  60. 8.10.5 Sanofi Pasteur Recent Developments
  61. 8.11 Protein Sciences Corporation
  62. 8.11.1 Protein Sciences Corporation Company Information
  63. 8.11.2 Protein Sciences Corporation Business Overview
  64. 8.11.3 Protein Sciences Corporation Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Protein Sciences Corporation Influenza Drugs Product Portfolio
  66. 8.11.5 Protein Sciences Corporation Recent Developments
  67. 8.12 Emergent Biosolutions
  68. 8.12.1 Emergent Biosolutions Company Information
  69. 8.12.2 Emergent Biosolutions Business Overview
  70. 8.12.3 Emergent Biosolutions Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Emergent Biosolutions Influenza Drugs Product Portfolio
  72. 8.12.5 Emergent Biosolutions Recent Developments
  73. 8.13 Celgene
  74. 8.13.1 Celgene Company Information
  75. 8.13.2 Celgene Business Overview
  76. 8.13.3 Celgene Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Celgene Influenza Drugs Product Portfolio
  78. 8.13.5 Celgene Recent Developments
  79. 8.14 Bristol-Myers Squibb]
  80. 8.14.1 Bristol-Myers Squibb] Company Information
  81. 8.14.2 Bristol-Myers Squibb] Business Overview
  82. 8.14.3 Bristol-Myers Squibb] Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb] Influenza Drugs Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb] Recent Developments
  85. 8.15 BioCryst Pharmaceuticals
  86. 8.15.1 BioCryst Pharmaceuticals Company Information
  87. 8.15.2 BioCryst Pharmaceuticals Business Overview
  88. 8.15.3 BioCryst Pharmaceuticals Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BioCryst Pharmaceuticals Influenza Drugs Product Portfolio
  90. 8.15.5 BioCryst Pharmaceuticals Recent Developments
  91. 8.16 Alvogen
  92. 8.16.1 Alvogen Company Information
  93. 8.16.2 Alvogen Business Overview
  94. 8.16.3 Alvogen Influenza Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Alvogen Influenza Drugs Product Portfolio
  96. 8.16.5 Alvogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Influenza Drugs Value Chain Analysis
  2. 9.1.1 Influenza Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Influenza Drugs Production Mode & Process
  6. 9.2 Influenza Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Influenza Drugs Distributors
  9. 9.2.3 Influenza Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst